Arcturus Therapeutics (ARCT) Q1 2025 Earnings
Arcturus Therapeutics reported Q1 2025 revenue of $29.4M (-9.9% YoY), beat analyst consensus of $23.3M by $6.0M. Diluted EPS came in at $-0.52 (+48.0% YoY), beat the $-1.58 consensus by $1.06.
Financial Snapshot
Trailing eight quarters through Q1 2025
Q1 2025 Earnings FAQ
Common questions about Arcturus Therapeutics's Q1 2025 earnings report.
Arcturus Therapeutics (ARCT) reported Q1 2025 earnings on May 12, 2025 after market close.
Arcturus Therapeutics reported revenue of $29.4M and diluted EPS of $-0.52 for Q1 2025.
Revenue beat the consensus estimate of $23.3M by $6.0M. EPS beat the consensus estimate of $-1.58 by $1.06.
Compared to the same quarter a year prior, revenue declined 9.9% from $32.6M a year earlier and diluted EPS grew 48.0% from $-1.00.
You can read the 10-Q periodic report (0000950170-25-069210) directly on SEC EDGAR. The filing index links above go to sec.gov.